Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

March 30, 2027

Study Completion Date

March 31, 2027

Conditions
Iron Deficiency AnemiaPregnancy
Interventions
DRUG

Ferric derisomaltose

Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes.

DRUG

Ferrous sulfate

325mg ferrous sulfate tablets (65 mg of elemental iron), 1 to 3 orally per day.

Trial Locations (8)

33143

RECRUITING

GNP Research at Heme-on-Call, Miami

35401

RECRUITING

University of Alabama Medical Center, Birmingham

48109

RECRUITING

Michigan University Medical Center, Ann Arbor

65105

RECRUITING

Washington University Medical Center, St Louis

84132

RECRUITING

University of Utah Hospital, Salt Lake City

97239

RECRUITING

Oregon Health and Sciences Uiversity Medical Center, Portland

02905

RECRUITING

Hasbro Children's Hospital, Providence

RECRUITING

Women & Infants Hospital of Rhode Island, Providence

All Listed Sponsors
collaborator

Hasbro Children's Hospital

OTHER

collaborator

University of Michigan

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

University of Utah

OTHER

collaborator

University of Alabama at Birmingham

OTHER

collaborator

Oregon Health and Science University

OTHER

collaborator

GNP Research at Heme-on-Call

UNKNOWN

lead

Women and Infants Hospital of Rhode Island

OTHER